BioCatalystWatch
AKBAWorkspace / AKBA / OverviewCompany library
Akebia Therapeutics, Inc. logo

Akebia Therapeutics, Inc.

Akebia Therapeutics, Inc. (AKBA)

Website

Price
Market cap
Next catalystExpected 2027Ebribafusp alfa (AKB-097) · Phase 2 dataSEC filing ↗
Cash

Chart & Events

Candle interval

Core Clinical

AKB-9090

HIF prolyl hydroxylase

PreINDP1P2P3FilingApproved
Upcoming / outlook

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

AKB-9090

HIF prolyl hydroxylase

PreINDP1P2P3FilingApproved
Upcoming / outlook

Other pipelines

AKB-9090

HIF prolyl hydroxylase

AKB-9090

HIF prolyl hydroxylase

Approved / commercial

HIF prolyl hydroxylase

History / paused

Ebribafusp alfa (AKB-097)

C3d

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

AKBA PR & News

PR & News

AKBA SEC archive